Ignite Creation Date:
2024-05-06 @ 3:27 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04631757
Status:
UNKNOWN
Last Update Posted:
2020-11-17
First Post:
2020-11-15
Brief Title:
Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction GEJ Adenocarcinoma
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-12-15
Start Date Type:
ESTIMATED
Primary Completion Date:
2022-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2020-11-15
First Submit QC Date:
November 15 2020
Study First Post Date:
2020-11-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-11-15
Last Update Post Date:
2020-11-17
Last Update Post Date Type:
ACTUAL